Aurobindo Pharma Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aurobindo Pharma Limited generated cash of $24,345,200,000, which is more than the previous year. Cash used in financing activities reached the amount of $8,004,200,000 last year. Net change in cash is therefore -$10,068,400,000.
Cash Flow
| 2010 | 4.28B | -3.99B | -876M |
|---|---|---|---|
| 2011 | 3.43B | -5.94B | 4.06B |
| 2012 | 3.26B | -5.63B | 1.18B |
| 2016 | 17.59B | -13.80B | -198.3M |
| 2018 | 19.54B | -19.56B | 8.64B |
| 2020 | 43.81B | -15.67B | -19.47B |
| 2021 | 33.28B | 5.98B | -13.64B |
| 2023 | 23.86B | -39.77B | 18.14B |
| 2024 | 24.34B | -45.36B | 8.00B |
AUROPHARMA.NS Cash Flow Statement (2010 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 43.92B | 41.62B | 27.46B | 18.75B | 3.19B | 4.61B | 1.83B | 447.2M | 1.02B |
Operating activities | |||||||||
Net income | 31.72B | 26.12B | 73.43B | 37.43B | 32.41B | 27.22B | -1.23B | 5.63B | 5.63B |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 14.91B | 12.44B | 10.55B | 9.66B | 5.57B | 3.92B | 2.00B | 1.71B | 1.49B |
Stock-based compensation expense | 89.1M | -57.5M | 86.2M | 0 | 100K | -5.5M | 0 | 0 | 0 |
| Deferred income tax benefit | 89.1M | -57.5M | 86.2M | 0 | 100K | -5.5M | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -2.64B | -4.32B | 7.44B | -6.56B | -656.6M | -11.10B | 0 | 0 | 0 |
Inventories | -13.03B | -9.26B | -15.93B | -5.26B | -14.12B | -4.76B | -902.9M | -3.75B | -2.22B |
Accounts payable | 5.82B | 7.07B | 1.26B | 2.95B | 3.96B | 4.45B | 0 | 0 | 0 |
Cash generated by operating activities | 24.34B | 23.86B | 33.28B | 43.81B | 19.54B | 17.59B | 3.26B | 3.43B | 4.28B |
Investing activities | |||||||||
Purchases Of Investments | -37.6M | -20.14B | -1.59B | -1.87B | -677.6M | -571.1M | 0 | 0 | -31.1M |
Investments In Property Plant And Equipment | -27.80B | -27.20B | -18.73B | -14.31B | -15.29B | -15.68B | -5.71B | -7.15B | -4.19B |
Acquisitions Net | 0 | -915.9M | 25.92B | -1.68B | -7.33B | 1.37B | 0 | 838.5M | 0 |
Cash generated by investing activities | -45.36B | -39.77B | 5.98B | -15.67B | -19.56B | -13.80B | -5.63B | -5.94B | -3.99B |
Financing activities | |||||||||
Common Stock Issued | 0 | 0 | 0 | 1.9M | 2.3M | 72M | 0 | 10.8M | 54.4M |
Payments for dividends | -2.63B | -4.39B | -2.34B | -1.88B | -2.19B | -1.34B | -338.2M | -474.7M | -288.5M |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 14.61B | 24.57B | -11.37B | -15.29B | 12.02B | 6.03B | -2.90B | -995.7M | -1.35B |
Cash used in financing activities | 8.00B | 18.14B | -13.64B | -19.47B | 8.64B | -198.3M | 1.18B | 4.06B | -876M |
Net Change In Cash | -10.06B | 2.29B | 25.83B | 8.71B | 8.92B | 3.63B | -1.18B | 1.41B | -554.6M |
Cash at end of period | 33.85B | 43.92B | 53.29B | 27.46B | 12.11B | 8.24B | 656.4M | 1.86B | 471.9M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |